Reata Pharmaceuticals: Reata's Acquisition Fits Biogen's Strategy Despite High Cost: Analyst Says High Level Regulatory Scrutiny Not Anticipated

Earlier today, Biogen Inc (NASDAQ: BIIB) agreed to acquire Reata Pharmaceuticals Inc (NASDAQ: RETA) for $172.50 per share in cash, reflecting an enterprise value of approximately $7.3 billion. William Blair analysts Myles Minter, Sarah Schram and Tiffany Marchell view the acquisition, although not inexpensive, as fitting the company's previously described acquisition goals of de-risked, value-added and accretive assets. The analysts say the asset and other pipeline Nrf2 activators fit well within the company's rare neurology franchise. William Blair also acknowledged potential competition over the longer term from other clinical-stage programs, ...Full story available on Benzinga.com